Ponesimod: An Oral Second-Generation Selective Sphingosine 1-Phosphate Receptor Modulator for the Treatment of Multiple Sclerosis.
Amal AlnaifIsabelle OilerManoranjan S D'SouzaPublished in: The Annals of pharmacotherapy (2022)
Currently available data suggest that ponesimod is a useful addition to other high-efficacy DMTs available to treat patients with MS.